Vascular endothelium plays a very important role in regulating vascular homeostasis. If the endothelium is damaged, this vascular lesion often leads to a cardiovascular disease, such as arteriosclerosis or spasms in the coronary artery. 1 Therefore, the detection and evaluation of vascular endothelium lesions in their early stage would be very important for effective diagnosis and therapy. However, no practical method for vascular lesionspecific detection has been reported as a practical diagnostic tool.
In this report, we describe a novel endothelium lesion-specific MRI (Magnetic Resonance Imaging) contrast agent, which has a dye component as a probing unit for the vascular lesion. In general, biomolecules such as antibodies, polysaccharides, or peptides have been used to recognize particular sites in biological systems. [2] [3] [4] However, such biomolecules are very expensive and are thus not practical for a contrast agent for blood vessels due to the large blood flow, in which a large amount of the agent would be needed. Therefore, we have looked for other less-expensive molecules that can recognize vascular endothelium lesions using the porcine aorta, and have at last found certain types of organic dyes to be useful for this purpose. In histochemistry, various dyes have been used for staining specific tissues and proteins. [5] [6] [7] These dyes can interact with their targets with high specificity. For example, Congo Red specifically binds to the amyloid beta protein. 7 In these dyes, Evans Blue has been used for staining a vascular endothelium injury. 8 Vascular endothelium forms a tight junction that regulates the molecular permeability into the vascular wall from the blood, 9 thereby providing a barrier in the vascular wall against blood flow. If the vascular endothelium is injured, many molecules begin to interact with the extracellular matrix and the vascular smooth muscle layer, which is located below the endothelium layer.
We have recently synthesized structural analogues of Evans Blue, and the dye unit was observed to selectively adsorb to a vascular endothelium-denuded region. We have therefore designed a new MRI-contrast agent that has Evans Blue analogue (Fig. 1) . The compound can be used as a contrast agent for the imaging of vascular lesions using MRI.
Experimental

Synthesis of N-tert.butoxycarbonyl-2,2′-dimethylbenzidine
2,2′-Dimethylbenzidine (3.00 g, 14.1 mmol) was dissolved in dichloromethane (25 ml), and Boc-anhydride (3.08 g, 14.1 mmol) was added dropwise at r.t. while stirring. After overnight stirring, the remaining dimethylbenzidine was removed by washing with saturated aqueous tartaric acid. The organic phase was then concentrated under reduced pressure. The residue was purified by column chromatography on silica gel using ethylacetate-hexane (3:5) as an eluting solvent. The A new MRI-contrast agent, EB-DTPA-Gd, that has an Evans Blue analogue as a sensing unit for endothelium lesions, was designed and synthesized. The agent also has diethylenetriamine-N,N,N′,N″,N″-pentaacetic acid-Gd complex (Gadolinium-DTPA) units, which have been used as detection units for T1-weighted MRI. The EB-DTPA-Gd was able to recognize and adsorb to the vascular endothelium-denuded region of porcine aorta, and to decrease the relaxation time of circumferential water's protons, making possible MR imaging of the endothelium-denuded region. The compound can be employed as a contrast agent for the imaging of vascular lesions using MRI. 
Synthesis of 2,2′-dimethylbenzidine-DTPA (DMB-DTPA)
N-tert.butoxycarbonyl-2,2′-dimethylbenzidine (0.281 g, 0.899 mmol) and DTPA anhydride (0.481 g, 1.35 mmol) were dissolved in dry DMSO (15 ml). The mixture was stirred at 40˚C. After 3 h, the reaction mixture was poured into cold water (500 ml). The precipitate was collected by filtration. The collected solid was put into water (2.8 ml), and the pH of the suspension was then adjusted to 7 with sodium carbonate. After neutralization, the solid was dissolved completely and then purified by ODS column chromatography using water-acetonitrile (3:1). The desired fraction was collected and then freeze-dried. The obtained solid was redissolved in TFA (5 ml), followed by stirring at r.t. for 1 h. This solution was poured into cold ether. The deposited solid was collected by filtration and dried under reduced pressure to obtain a colorless solid (0.133 g, 14%). The chemical structure was characterized as TFA salts (DMB-DTPA·4TFA) by 1 H-NMR and elemental analysis.
Synthesis of EB-DTPA
All reactions were performed in an ice bath. DMB-DTPA·4TFA (51.1 mg, 49.0 mmol) was dissolved in water (1 ml) containing HCl (147 µmol). Sodium nitrite (3.38 mg, 49.0 µmol) was then added in small portions, followed by stirring for 20 min. A diazonium salt solution was added dropwise into 1 ml of an aqueous 1-amino-8-naphtol-2,4-disulfonic acid (16.7 mg, 49.9 µmol) solution containing sodium bicarbonate (16.5 mg, 196 µmol), and then stirred for 3 h. The reaction mixture was lyophilized. The concentrate was redissolved in water (1 ml), and the desired product was precipitated by conc. hydrochloric acid (36.5 mg, 81%). The precipitate was collected and dried under reduced pressure. The chemical structure was determined by 1 H-NMR and elemental analysis.
MRI experimental procedure
An aqueous MRI contrast agent solution was prepared as follows. EB-DTPA was dissolved in deionized water to be 1 -15 mM, and a 1 M aqueous gadolinium chloride solution containing equimolar gadolinium ion to EB-DTPA was added.
The pH of the solution was adjusted to 7 with a 1 M aqueous sodium hydroxide solution.
An extracted porcine aorta was opened to a flat sheet. The endothelium in the left-half area from the center axis was then removed with a scalpel, while the right-half area was allowed to remain intact (Fig. 2a) . The aorta section was dipped with the MRI contrast agent solution for 10 s, and then washed with saline. The aorta section was evaluated by MR Imaging (1.5T MAGNETOM VISION system (SIEMENS, Germany), T1-weighted Spin Echo, TR/TE=400/14 ms, 3 mm slice thickness, field-of-view 50 mm and dot matrix 128*256). The obtained MRI image was analyzed with the NIH image.
Results and Discussion
The MRI contrast agent was successfully obtained as a pure compound by the preparation protocol described in the experimental section. We therefore investigated whether the molecule selectively bound to an endothelium-broken site in a blood-vessel sample.
A photograph of the porcine aorta stained with 10 mM aqueous MRI contrast agent, EB-DTPA-Gd, is shown in Fig.  2b . Although a slight nonspecific binding of the agent was observed in the intact endothelium region, a clear accumulation of the synthesized contrast agent was observed in the endothelium-removed region. Figure 2c shows an MRI image, giving a top view. The endothelium-intact area and the damaged area can be distinguished by T1-weighted MR imaging. Figure 2d shows an MRI image of the same aorta section, but a side view, and a histogram of the MR signal intensity on the inner-surface region of the aorta section. The stained section shows that the MRI signal enhancement can only be seen in the inner-surface area of the aorta wall, which means that EB-DTPA-Gd did not permeate the tissue from the endothelium barrier-injured site. This result is quite important because the MR imaging agent for blood vessels should be excreted rapidly after the MR image is taken; otherwise, an undesired effect might result. In the localization of the agent at the surface area, the polar group in the Evans Blue-related structure may be requisite. Actually, the MR-signal using DMB-DTPA-Gd, which lacked the 2,4-disulfonyl-1-amino-8-naphtol unit from EB-DTPA-Gd, was seen even in the smooth muscle layer of the aorta strip due to infiltration of the compound (Fig. 3b) . In contrast, an ordinary MRI-contrast agent, DTPA-Gd, which had no hydrophobic unit, did not adsorb on the inner surface of the aorta sample. These results indicate that the endothelium lesion-selective contrast agent should have a chemical structure that is hydrophobic, but that at the same time has some hydrophilic groups. For the next experiment, the concentration dependency of the MRI signal of the EB-DTPA-Gd of endothelium lesion was evaluated to determine the minimal dose. First, the contrast agent was evaluated (Fig. 4) . The MRI signal intensity was gradually increased in the endothelium-damaged area along with increases in the EB-DTPA-Gd concentrations. In contrast, the MRI signals of the endothelium-intact area were found to be independent of the agent concentrations. The increment of the signal intensity was nearly saturated at agent concentrations of 10 mM on the lesional area. Thus, we determined that 10 mM is sufficient to detect the target area. The signal increment when using of 10 mM EB-DTPA-Gd was nearly 1.5-times that of the intact area.
Endothelium lesions often cause vascular diseases. For the diagnosis of such an endothelium-damaged site, we tried to design an MRI-contrast agent that can bind to such a vascular injury site.
After a wide range of screening, we finally found some organic azo-dyes that could potentially be used as a probing unit for endothelium lesions, and Evans Blue was found to be the best candidate among these dyes. Thus, we designed a new MRI contrast agent, EB-DTPA-Gd, having an Evans Bluerelated structure. Newly synthesized EB-DTPA-Gd showed endothelium lesion-specific adsorption in an in vitro experiment. The reagent was also able to detect the lesional site using T1-weighted MR-imaging. This compound would potentially be able to be used as an MR imaging probe to detect vascular damage. We are now investigating the use of this compound in ex vivo and in vivo trials. These results will be reported in due course. 
